A comprehensive serum lipidome profiling of amyotrophic lateral sclerosis

References

• van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–98.
   PubMed Web of Science ®Google Scholar
• Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74:525–32.
   PubMed Web of Science ®Google Scholar
• Lu C-H, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247–57.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90:e22–30.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig. 2014;4:605–18.
   PubMedGoogle Scholar
• Steyn FJ, Ioannides ZA, van Eijk RPA, Heggie S, Thorpe KA, Ceslis A, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry. 2018;89:1016–23.
   PubMed Web of Science ®Google Scholar
• Jésus P, Fayemendy P, Nicol M, Lautrette G, Sourisseau H, Preux P-M, et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2018;25:97–104.
   PubMed Web of Science ®Google Scholar
• Zufiría M, Gil-Bea FJ, Fernández-Torrón R, Poza JJ, Muñoz-Blanco JL, Rojas-García R, et al. ALS: a bucket of genes, environment, metabolism and unknown ingredients. Prog Neurobiol. 2016;142:104–29.
   PubMed Web of Science ®Google Scholar
• Chiang P-M, Ling J, Jeong YH, Price DL, Aja SM, Wong PC. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc Natl Acad Sci USA. 2010;107:16320–4.
   PubMed Web of Science ®Google Scholar
• Fergani A, Oudart H, Gonzalez De Aguilar J-L, Fricker B, René F, Hocquette J-F, et al. Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J Lipid Res. 2007;48:1571–80.
   PubMed Web of Science ®Google Scholar
• Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig-Grosch S, Henriques A, et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med. 2015;7:526–46.
   PubMed Web of Science ®Google Scholar
• Dobrowolny G, Lepore E, Martini M, Barberi L, Nunn A, Scicchitano BM, et al. Metabolic changes associated with muscle expression of SOD1G93A. Front Physiol. 2018;9:831.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar J-L, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004–9.
   PubMed Web of Science ®Google Scholar
• Dorst J, Kühnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258:613–7.
   PubMed Web of Science ®Google Scholar
• Huang R, Guo X, Chen X, Zheng Z, Wei Q, Cao B, et al. The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. Amyotroph Lateral Scler Front Degener. 2015;16:359–65.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Sui Y, Gao W, Cai B, Fan D. Effects of diet on adenosine monophosphate-activated protein kinase activity and disease progression in an amyotrophic lateral sclerosis model. J Int Med Res. 2015;43:67–79.
   PubMed Web of Science ®Google Scholar
• Kim B, Jin Y, Kim SH, Park Y. Association between macronutrient intake and amyotrophic lateral sclerosis prognosis. Nutr Neurosci. 2018;23:8–15.
   PubMed Web of Science ®Google Scholar
• Fitzgerald KC, O’Reilly ÉJ, Falcone GJ, McCullough ML, Park Y, Kolonel LN, et al. Dietary ω-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:1102.
   PubMed Web of Science ®Google Scholar
• Chiò A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73:1681–5.
   PubMed Web of Science ®Google Scholar
• Lydic TA, Goo Y-H. Lipidomics unveils the complexity of the lipidome in metabolic diseases. Clin Transl Med. 2018;7:26.
   PubMed Web of Science ®Google Scholar
• Burla B, Arita M, Arita M, Bendt AK, Cazenave-Gassiot A, Dennis EA, et al. MS-based lipidomics of human blood plasma: a community-initiated position paper to develop accepted guidelines. J Lipid Res. 2018;59:2001–17.
   PubMed Web of Science ®Google Scholar
• Alonso C, Fernández-Ramos D, Varela-Rey M, Martínez-Arranz I, Navasa N, Van Liempd SM, et al. Metabolomic identification of subtypes of nonalcoholic steatohepatitis. Gastroenterology. 2017;152:1449.e7–61.e7.
   Web of Science ®Google Scholar
• Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills A-M. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44:20–4.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51:1501–8.
   PubMed Web of Science ®Google Scholar
• Yang JW, Kim S-M, Kim H-J, Kim J-E, Park KS, Kim S-H, et al. Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference? J Clin Neurol. 2013;9:125–9.
   PubMed Web of Science ®Google Scholar
• Delaye JB, Patin F, Piver E, Bruno C, Vasse M, Vourc’h P, et al. Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients. J Neurol Sci. 2017;380:124–7.
   PubMed Web of Science ®Google Scholar
• Blasco H, Veyrat-Durebex C, Bocca C, Patin F, Vourc’h P, Kouassi Nzoughet J, et al. Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci Rep. 2017;7:17652.
   PubMed Web of Science ®Google Scholar
• Blasco H, Patin F, Descat A, Garçon G, Corcia P, Gelé P, et al. A pharmaco-metabolomics approach in a clinical trial of ALS: identification of predictive markers of progression. PLoS One. 2018;13:e0198116.
   PubMed Web of Science ®Google Scholar
• Wuolikainen A, Jonsson P, Ahnlund M, Antti H, Marklund SL, Moritz T, et al. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson’s disease and control subjects. Mol Biosyst. 2016;12:1287–98.
   PubMedGoogle Scholar
• Trupp M, Jonsson P, Ohrfelt A, Zetterberg H, Obudulu O, Malm L, et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson’s disease. J Parkinsons Dis. 2014;4:549–60.
   PubMedGoogle Scholar
• Bjornevik K, Zhang Z, O’Reilly ÉJ, Berry JD, Clish CB, Deik A, et al. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019;92:e2089–100.
   PubMed Web of Science ®Google Scholar
• Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, et al. Elevated GM3 plasma concentration in idiopathic Parkinson’s disease: a lipidomic analysis. PLoS One. 2017;12:e0172348.
   PubMed Web of Science ®Google Scholar
• Proitsi P, Kim M, Whiley L, Simmons A, Sattlecker M, Velayudhan L, et al. Association of blood lipids with Alzheimer’s disease: a comprehensive lipidomics analysis. Alzheimer’s Dement. 2017;13:140–51.
   PubMed Web of Science ®Google Scholar
• Simpson BN, Kim M, Chuang Y-F, Beason-Held L, Kitner-Triolo M, Kraut M, et al. Blood metabolite markers of cognitive performance and brain function in aging. J Cereb Blood Flow Metab. 2016;36:1212–23.
   PubMed Web of Science ®Google Scholar
• Abdullahi A, Jeschke MG. White adipose tissue browning: a double-edged sword. Trends Endocrinol Metab. 2016;27:542–52.
   PubMed Web of Science ®Google Scholar
• Nair KS, Halliday D, Garrow JS. Increased energy expenditure in poorly controlled Type 1 (insulin-dependent) diabetic patients. Diabetologia. 1984;27:13–6.
   PubMed Web of Science ®Google Scholar
• Nodera H, Takamatsu N, Muguruma N, Ukimoto K, Nishio S, Oda M, et al. Frequent hepatic steatosis in amyotrophic lateral sclerosis: implication for systemic involvement. Neurol Clin Neurosci. 2015;3(2):58–62.
   Web of Science ®Google Scholar
• Schönfeld P, Reiser G. Why does brain metabolism not favor burning of fatty acids to provide energy-reflections on disadvantages of the use of free fatty acids as fuel for brain. J Cereb Blood Flow Metab. 2013;33:1493–9.
   PubMed Web of Science ®Google Scholar
• O’Reilly ÉJ, Bjornevik K, Furtado JD, Kolonel LN, Le Marchand L, McCullough ML, et al. Prediagnostic plasma polyunsaturated fatty acids and the risk of amyotrophic lateral sclerosis. Neurology. 2019. doi:10.1212/WNL.0000000000008676
   Web of Science ®Google Scholar
• Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75–82.
   PubMed Web of Science ®Google Scholar
• Szelechowski M, Amoedo N, Obre E, Léger C, Allard L, Bonneu M, et al. Metabolic reprogramming in amyotrophic lateral sclerosis. Sci Rep. 2018;8:3953.
   PubMed Web of Science ®Google Scholar
• Du Y, Wen Y, Guo X, Hao J, Wang W, He A, et al. A genome-wide expression association analysis identifies genes and pathways associated with amyotrophic lateral sclerosis. Cell Mol Neurobiol. 2018;38:635–9.
   PubMed Web of Science ®Google Scholar
• Mitchell J, Paul P, Chen H-J, Morris A, Payling M, Falchi M, et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci USA. 2010;107:7556–61.
   PubMed Web of Science ®Google Scholar
• Staprans I, Pan XM, Rapp JH, Feingold KR. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis. Mol Nutr Food Res. 2005;49:1075–82.
   PubMed Web of Science ®Google Scholar
• Ilieva EV, Ayala V, Jove M, Dalfo E, Cacabelos D, Povedano M, et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007;130:3111–23.
   PubMed Web of Science ®Google Scholar
• Sandhir R, Khan M, Chahal A, Singh I. Localization of nervonic acid beta-oxidation in human and rodent peroxisomes: impaired oxidation in Zellweger syndrome and X-linked adrenoleukodystrophy. J Lipid Res. 1998;39:2161–71.
   PubMed Web of Science ®Google Scholar
• Lee G, Hasan M, Kwon O-S, Jung BH. Identification of altered metabolic pathways during disease progression in EAE mice via metabolomics and lipidomics. Neuroscience. 2019;416:74–87.
   PubMed Web of Science ®Google Scholar
• Menke RAL, Gray E, Lu C-H, Kuhle J, Talbot K, Malaspina A, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015;2:748–55.
   PubMed Web of Science ®Google Scholar
• Iwabuchi K, Nakayama H, Iwahara C, Takamori K. Significance of glycosphingolipid fatty acid chain length on membrane microdomain-mediated signal transduction. FEBS Lett. 2010;584:1642–52.
   PubMed Web of Science ®Google Scholar
• Courtney KC, Pezeshkian W, Raghupathy R, Zhang C, Darbyson A, Ipsen JH, et al. C24 sphingolipids govern the transbilayer asymmetry of cholesterol and lateral organization of model and live-cell plasma membranes. Cell Rep. 2018;24:1037–2018.
   PubMed Web of Science ®Google Scholar
• Bernard-Marissal N, Chrast R, Schneider BL. Endoplasmic reticulum and mitochondria in diseases of motor and sensory neurons: a broken relationship? Cell Death Dis. 2018;9:333.
   PubMed Web of Science ®Google Scholar
• Flowers MT, Ntambi JM. Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr Opin Lipidol. 2008;19:248–56.
   PubMed Web of Science ®Google Scholar
• Hussain G, Schmitt F, Henriques A, Lequeu T, Rene F, Bindler F, et al. Systemic down-regulation of delta-9 desaturase promotes muscle oxidative metabolism and accelerates muscle function recovery following nerve injury. PLoS One. 2013;8:e64525.
   PubMed Web of Science ®Google Scholar
• ALJohani AM, Syed DN, Ntambi JM. Insights into stearoyl-CoA desaturase-1 regulation of systemic metabolism. Trends Endocrinol Metab. 2017;28:831–42.
   PubMed Web of Science ®Google Scholar
• Henriques A, Blasco H, Fleury M-C, Corcia P, Echaniz-Laguna A, Robelin L, et al. Blood cell palmitoleate–palmitate ratio is an independent prognostic factor for amyotrophic lateral sclerosis. PLoS One. 2015;10:e0131512.
   PubMed Web of Science ®Google Scholar